Coffer A I, Spiller G H, Lewis K M, King R J
Cancer Res. 1985 Aug;45(8):3694-8.
A human specific monoclonal antibody (D5) raised against a Mr 36,000 cytosolic estrogen receptor component (RE) partially purified from human myometrium was used to develop a simple, rapid, and sensitive solid-phase immunoradiometric assay (IRMA) for the reactive antigen in tissue cytosols from breast tumors, myometrium, endometrium, and endometrial carcinomas. The IRMA did not detect antigen in RE-negative cytosols from human breast tumors and endometrial carcinomas. RE-positive cytosols from chick oviduct and calf and rat uteri failed to produce an IRMA response. A pilot study indicated a significant correlation (P less than 0.001) between D5 IRMA value and RE sites in breast tumors assayed by [3H]estradiol binding sites. The presence of D5 antigen was dependent on the presence of cytosolic RE but not progesterone receptor. RE-positive patients age 50 years and over demonstrated significantly higher D5 assay values than did patients under 50 years. The data suggest that the D5 antigen is a component of the estrogen receptor or coordinately regulated with the receptor in human cells and that the assay method may have clinical use.
一种针对从人子宫肌层中部分纯化的分子量为36,000的胞质雌激素受体成分（RE）产生的人特异性单克隆抗体（D5），被用于开发一种简单、快速且灵敏的固相免疫放射分析（IRMA），以检测来自乳腺肿瘤、子宫肌层、子宫内膜和子宫内膜癌的组织胞质溶胶中的反应性抗原。该IRMA在来自人乳腺肿瘤和子宫内膜癌的RE阴性胞质溶胶中未检测到抗原。来自鸡输卵管、小牛和大鼠子宫的RE阳性胞质溶胶未能产生IRMA反应。一项初步研究表明，通过[3H]雌二醇结合位点检测的乳腺肿瘤中，D5 IRMA值与RE位点之间存在显著相关性（P小于0.001）。D5抗原的存在依赖于胞质RE的存在，但不依赖于孕激素受体。50岁及以上的RE阳性患者的D5检测值显著高于50岁以下的患者。数据表明，D5抗原是雌激素受体的一个成分，或在人细胞中与该受体协同调节，并且该检测方法可能具有临床应用价值。
